EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) finished Wednesday with an addition of $0.09 to close at $2.06, an upside of 4.57 percent. An average of 1,351,700 shares of common stock have been traded in the last five days. There was a gain of $0.2700 in the past week. The last 20 days have seen an average of 2,707,305 shares traded, while the 50-day average volume stands at 2,121,908.
EYEG stock has increased by 14.44% in the last month. The company shares reached their 1-month lowest point of $1.7100 on 09/14/21. With the stock rallying to its 52-week high on 02/17/21, shares of the company touched a low of $1.44 and a high of $8.18 in 52 weeks. In spite of this, the price is down -74.82% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
73 days have passed since EyeGate Pharmaceuticals Inc. (EYEG) last reported insider trading activity. ARMISTICE CAPITAL, LLC, who is 10% Owner, most recently acquired $192,775 shares at $2.40 per share on Aug 02. In this transaction, the insider spent $463,046. 10% Owner, ARMISTICE CAPITAL, LLC, disposed of 68,188 shares at a price of $2.69 on Jul 30. The insider now owns more than $183,562 worth of shares. Prior to that, Director ARMISTICE CAPITAL, LLC went on to Sale 400,000 shares at $3.00 each on Jul 29. An amount of $1,200,000 was transacted.
EyeGate Pharmaceuticals Inc. (EYEG) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 0.88. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2169.50, the price-to-book (PB) ratio at 1.39.
The quick ratio of EyeGate Pharmaceuticals Inc. for the three months ended June 29 was 3.10, and the current ratio was 3.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. EyeGate Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -66444.48%. Its gross profit as reported stood at $8.22 million compared to revenue of $12000.0.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, EyeGate Pharmaceuticals Inc.’s return on assets was -60.00%, compared to -137.4% over the last five years. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated EyeGate Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.42 per share, but it turned out to be -$0.35, a 16.70% surprise. For the quarter, EBITDA amounted to -$2.73 million. Shareholders own equity worth $12.62 million.
From a technical analysis perspective, let’s take a brief look at EyeGate Pharmaceuticals Inc. (EYEG) price momentum. RSI 9-day as of the close on 13 October was 60.18%, suggesting the stock is Neutral, with historical volatility in this time frame at 87.07%.
As of today, EYEG’s price is $1.9300 +15.08% or $0.2700 from its 5-day moving average. EYEG is currently trading +5.64% higher than its 20-day SMA and -52.59% lower than its 100-day SMA. However, the stock’s current price level is -21.37% below the SMA50 and -59.05% below the SMA200.
The stochastic %K and %D were 40.44% and 30.78%, respectively, and the average true range (ATR) was 0.1800. With the 14-day stochastic at 54.10% and the average true range at 0.1900, the RSI (14) stands at 55.53%. The stock has reached 0.0800 on the 9-day MACD Oscillator while the 14-day reading was at 0.0500.
H.C. Wainwright reiterated its a Buy rating on EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), but raised their price target to $10, indicating a potential price increase of 385.44% for the stock.The consensus rating for EyeGate Pharmaceuticals Inc. (EYEG) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell EYEG, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is EYEG’s price target for the next 12 months?
Analysts predict a range of price targets between $9.50 and $15.00, with a median target of $11.00. Taking a look at these predictions, the average price target given by analysts for EyeGate Pharmaceuticals Inc. (EYEG) stock is $11.83.